FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm with a market capitalization of $72.47 billion, declared a quarterly dividend and the ...

The company also announced it repurchased $750 million in BD stock to date in fiscal 2025. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in ...

The global lateral flow assay (LFA) market, valued at USD 4.3 billion in 2023, is projected to grow steadily at a CAGR of 4.7 ...

Babson Diagnostics, a science-first healthcare technology company, today announced that BetterWay™ blood testing is a ...

Company will spotlight sustainable solutions to enhance patient safety, workforce well-being, and care delivery efficiency ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

BD invested $10 million last year to increase manufacturing capacity. The recent expansion has created more than 200 jobs.

Overall, BD is expected to increase its production of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by more than 50%. The manufacturer has ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy ...